Promising combo tackles Hard-to-Treat breast cancer
NCT ID NCT02705859
First seen Apr 17, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This early-phase trial tested a combination of two drugs—copanlisib and trastuzumab—in 26 women with advanced HER2-positive breast cancer that had worsened after prior treatment. The goal was to find the safest dose and see if the combination could shrink tumors or slow disease progression. Results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Trials Ireland Investigative Site
Cork, Ireland
-
Cancer Trials Ireland Investigative Site
Dublin, Ireland
-
Cancer Trials Ireland Investigative Site
Galway, Ireland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copanlisib (a targeted cancer drug) combined with trastuzumab (Herceptin)
What this could lead to
If successful, this combination could offer a new treatment option for patients with HER2-positive breast cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 26 participants, so results may not apply broadly. The drug combination may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.